210 related articles for article (PubMed ID: 32105728)
1. Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases.
Kochar B; Cai W; Cagan A; Ananthakrishnan AN
Gastroenterology; 2020 Jun; 158(8):2104-2111.e2. PubMed ID: 32105728
[TBL] [Abstract][Full Text] [Related]
2. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
Clin Transl Gastroenterol; 2021 Jul; 12(7):e00380. PubMed ID: 34228004
[TBL] [Abstract][Full Text] [Related]
3. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
4. Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases.
Alvisi P; Dipasquale V; Barabino A; Martellossi S; Miele E; Lionetti P; Lombardi G; Cucchiara S; Torre G; Romano C
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):957-961. PubMed ID: 31490707
[No Abstract] [Full Text] [Related]
5. Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
Hradsky O; Copova I; Zarubova K; Durilova M; Nevoral J; Maminak M; Hubacek P; Bronsky J
Dig Dis Sci; 2015 Nov; 60(11):3399-407. PubMed ID: 26091801
[TBL] [Abstract][Full Text] [Related]
6. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.
Borman ZA; Côté-Daigneault J; Colombel JF
Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1101-1108. PubMed ID: 30277409
[TBL] [Abstract][Full Text] [Related]
7. Preventing infective complications in inflammatory bowel disease.
Mill J; Lawrance IC
World J Gastroenterol; 2014 Aug; 20(29):9691-8. PubMed ID: 25110408
[TBL] [Abstract][Full Text] [Related]
8. Better survival of renal cell carcinoma in patients with inflammatory bowel disease.
Derikx LA; Nissen LH; Drenth JP; van Herpen CM; Kievit W; Verhoeven RH; Mulders PF; Hulsbergen-van de Kaa CA; Boers-Sonderen MJ; van den Heuvel TR; Pierik M; Nagtegaal ID; Hoentjen F; ; ;
Oncotarget; 2015 Nov; 6(35):38336-47. PubMed ID: 26447542
[TBL] [Abstract][Full Text] [Related]
9. Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.
Kurti Z; Lovasz BD; Gecse KB; Balint A; Farkas K; Morocza-Szabo A; Gyurcsanyi A; Kristof K; Vegh Z; Gonczi L; Kiss LS; Golovics PA; Lakatos L; Molnar T; Lakatos PL
J Gastrointestin Liver Dis; 2015 Dec; 24(4):467-72. PubMed ID: 26697573
[TBL] [Abstract][Full Text] [Related]
10. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease.
Horst S; Chao A; Rosen M; Nohl A; Duley C; Wagnon JH; Beaulieu DB; Taylor W; Gaines L; Schwartz DA
Dig Dis Sci; 2015 Feb; 60(2):465-70. PubMed ID: 25274158
[TBL] [Abstract][Full Text] [Related]
11. Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease.
Pratt PK; Nunes D; Long MT; Farraye FA
Dig Dis Sci; 2019 Jul; 64(7):2031-2038. PubMed ID: 30945037
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
13. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.
Fiorino G; Peyrin-Biroulet L; Naccarato P; Szabò H; Sociale OR; Vetrano S; Fries W; Montanelli A; Repici A; Malesci A; Danese S
Inflamm Bowel Dis; 2012 Jun; 18(6):1042-7. PubMed ID: 21674732
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease.
Caldera F; Misch EA; Saha S; Wald A; Zhang Y; Hubers J; Megna B; Ley D; Reichelderfer M; Hayney MS
Dig Dis Sci; 2019 Jan; 64(1):189-195. PubMed ID: 30317494
[TBL] [Abstract][Full Text] [Related]
15. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence.
Hissong E; Chen Z; Yantiss RK
Mod Pathol; 2019 Jul; 32(8):1210-1216. PubMed ID: 30952971
[TBL] [Abstract][Full Text] [Related]
17. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
19. Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study.
Goren I; Brom A; Yanai H; Dagan A; Segal G; Israel A
United European Gastroenterol J; 2020 Mar; 8(2):195-203. PubMed ID: 32213075
[TBL] [Abstract][Full Text] [Related]
20. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
